Literature DB >> 32728806

Statement of the German Ophthalmological Society (DOG), the German Retina Society (GRS), and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration : Status February 2020.

.   

Abstract

Entities:  

Year:  2021        PMID： 32728806     DOI： 10.1007/s00347-020-01188-1

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


× No keyword cloud information.
  29 in total

1.  TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Authors:  Daniel Barthelmes; Vuong Nguyen; Vincent Daien; Anna Campain; Richard Walton; Robyn Guymer; Nigel Morlet; Alex P Hunyor; Rohan W Essex; Jennifer J Arnold; Mark C Gillies
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

2.  Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years.

Authors:  Farshad Abedi; Sanjeewa Wickremasinghe; Amirul F M Islam; Kellie M Inglis; Robyn H Guymer
Journal:  Retina       Date:  2014-08       Impact factor: 4.256

3.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.

Authors:  Pravin U Dugel; Adrian Koh; Yuichiro Ogura; Glenn J Jaffe; Ursula Schmidt-Erfurth; David M Brown; Andre V Gomes; James Warburton; Andreas Weichselberger; Frank G Holz
Journal:  Ophthalmology       Date:  2019-04-12       Impact factor: 12.079

5.  Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study.

Authors:  Michèle Augsburger; Gian-Marco Sarra; Pascal Imesch
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-06-29       Impact factor: 3.117

6.  Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.

Authors:  Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Lucy A Culliford; Barnaby C Reeves
Journal:  Lancet       Date:  2013-07-19       Impact factor: 79.321

7.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

Authors:  David M Brown; Mark Michels; Peter K Kaiser; Jeffrey S Heier; Judy P Sy; Tsontcho Ianchulev
Journal:  Ophthalmology       Date:  2009-01       Impact factor: 12.079

8.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors:  Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2012-10-17       Impact factor: 12.079

9.  Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.

Authors:  Karina Berg; Terje R Pedersen; Leiv Sandvik; Ragnheiður Bragadóttir
Journal:  Ophthalmology       Date:  2014-09-13       Impact factor: 12.079
View more
  3 in total

1.  First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration.

Authors:  Alaa Din Abdin; Wissam Aljundi; Khalil El Jawhari; Shady Suffo; Isabel Weinstein; Berthold Seitz
Journal:  Front Pharmacol       Date:  2022-05-30       Impact factor: 5.988

2.  Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration.

Authors:  Bianka Sobolewska; Muhammed Sabsabi; Focke Ziemssen
Journal:  Clin Ophthalmol       Date:  2021-10-27

Review 3.  The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice.

Authors:  Ian Pearce; Winfried Amoaku; Clare Bailey; Louise Downey; Richard Gale; Faruque Ghanchi; Robin Hamilton; Sajjad Mahmood; Geeta Menon; Jenny Nosek; James Talks; Yit Yang
Journal:  Eye (Lond)       Date:  2022-03-21       Impact factor: 4.456
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.